Sitemap Contact Privacy Statement Imprint

Mass Spectrometry-Based Targeted and Non-Targeted Metabolomics/Lipidomics

Metabolomics, the large-scale analysis of small molecules and lipids in biological samples, is a rapidly emerging discipline in pharmacological research. Its ability to monitor downstream products of genomic, transcriptomic and/or proteomic alterations offers great potential for the molecular characterization of disease and drug-induced phenotypes. In addition to pharmacogenomic approaches metabolomics is increasingly used as a complementary tool that will promote the idea of system biology and pathway-driven research. The aim of our research focusses on the development and application of methods for the identification and quantification of metabolites in body fluids (e.g. serum, urine), tissues and cells. Employing state-of-the-art mass spectrometry (LC-ESI-MS/MS) we pursue two different strategies: (1) a targeted approach for the absolute quantification of known metabolites in biological samples and (2) a non-targeted strategy which enables the profiling of disease- and drug-induced perturbations of global metabolic patterns. Moreover, the latter strategy offers great potential for the identification of new diagnostic and prognostic biomarkers.

Major Projects
  • Quantitative profiling of bile acids during clinical drug development
  • Identification and analysis of novel predictors for the prognosis and/or therapy of kidney cancer
 Dr. Mathias Haag

phone: ++49-711-8101 5429

Selected References
  • Haag M, Hofmann U, Mürdter TE, Heinkele G, Leuthold P, Blank A, Haefeli WE, Alexandrov A, Urban S, Schwab M. Quantitative bile acid profiling by liquid chromatography quadrupole time-of-flight mass spectrometry: monitoring hepatitis B therapy by a novel Na+-taurocholate cotransporting polypeptide inhibitor. Anal Bioanal Chem. 2015 Jul 5. [Epub ahead of print]
  • Urban S, Bogomolov P, Voronkova N, Allweiss L, Dandri M, Schwab M, Lempp FA, Haag M, Wedemeyer H, Alexandrov A. A proof-of-concept Phase 2a clinical trial with HBV/HDV entry inhibitor Myrcludex B.Hepatology 2014 October Vol. 60/1; LB-20
  • Richter-Dennerlein R, Korwitz A, Haag M, Tatsuta T, Dargazanli S, Baker M, Decker T, Lamkemeyer T, Rugarli EI, Langer T. DNAJC19, a Mitochondrial Cochaperone Associated with Cardiomyopathy, Forms a Complex with Prohibitins to Regulate Cardiolipin Remodeling. Cell Metab. 2014 Jul 1;20(1):158-71.
  • Potting C, Tatsuta T, König T, Haag M, Wai T, Aaltonen MJ, Langer T. TRIAP1/PRELI complexes prevent apoptosis by mediating intramitochondrial transport of phosphatidic acid. Cell Metab. 2013 Aug 6;18(2):287-95.
  • Connerth M, Tatsuta T, Haag M, Klecker T, Westermann B, Langer T. Intramitochondrial transport of phosphatidic acid in yeast by a lipid transfer protein. Science. 2012 Nov 9;338(6108):815-8.
  • Haag, M.; Schmidt, A.; Sachsenheimer, T.; Brügger, B. Quantification of Signaling Lipids by Nano-Electrospray Ionization Tandem Mass Spectrometry (Nano-ESI MS/MS). Metabolites. 2012 Jan 2, 57-76.
  • Schmidt A, Oberle N, Weiss EM, Vobis D, Frischbutter S, Baumgrass R, Falk CS, Haag M, Brügger B, Lin H, Mayr GW, Reichardt P, Gunzer M, Suri-Payer E, Krammer PH. Human regulatory T cells rapidly suppress T cell receptor-induced Ca(2+), NF-?B, and NFAT signaling in conventional T cells. Sci Signal. 2011 Dec 20;4(204):ra90.
  • Sahlmüller MC, Strating JR, Beck R, Eckert P, Popoff V, Haag M, Hellwig A, Berger I, Brügger B, Wieland FT. Recombinant heptameric coatomer complexes: novel tools to study isoform-specific functions. Traffic. 2011 Jun;12(6):682-92.

Curriculum Vitae Mathias Haag, PhD

Senior scientist

Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology
Auerbachstr. 112
D - 70376 Stuttgart, Germany
phone: ++49-711-8101-5429
fax: ++49-711-85 92 95
Education and Professional Career
 2001-2006 Studies in Biotechnology at the University of Applied Sciences in Darmstadt, Germany
  2006 Diploma thesis in the Preclinical R&D Department at Merck KGaA in Darmstadt, Germany (Dr. Roland Kellner): “Characterization of Native and Recombinant Allergens with Protein Analytical Methods”
  2006-2011 PhD thesis and postdoctoral fellow at the Heidelberg University Biochemistry Center in Heidelberg, Germany (Prof. Dr. Felix Wieland and PD. Dr. Britta Brügger): “Development of Mass Spectrometric Methods for the Quantification of Membrane Lipids – Studies on Mitochondria, T Cells, Golgi Membranes and COPI Vesicles”
  2011-2013 Postdoctoral fellow at the Institute for Genetics of the University of Cologne, Germany (Prof. Dr. Thomas Langer): “Establishment of Mass Spectrometric Methods for the Quantification of Mitochondrial Phospholipids”
  since 2013 Senior scientist at the Dr. Margarete Fischer-Bosch-Institute for Clinical Pharmacology in Stuttgart, Germany (Prof. Dr. Matthias Schwab): “Mass Spectrometry-Based Targeted and Non-Targeted Metabolomics and Lipidomics”